/

LKFT

Lakefront BiotherapeuticsPre-market

29.05−0.52 −1.76%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayPre-market 29.08 +0.10%

Open

29.41

Prev close

29.57

Day range

29.0429.62

52-week range

25.6836.24

Volume

175.87K0.63×

Mkt cap

1.90B

P/E ttm

2.76

Fwd P/E

-24.56

EPS ttm

10.52

Div yield

0.00%

Earnings

Nov 11, 2026

From 52w high

−19.84%

Price Chart

Yahoo Finance · delayed

LKFTOct 13, 2026O 29.42H 29.62L 29.04C 29.05−0.52 (−1.76%)Vol 175.90K

SMA 5028.58
SMA 20030.05

1Y change −14.36% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LKFT Lakefront Biotherapeutics · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.92%
1 month: +8.36%
3 months: −1.43%
6 months: +0.59%
Year to date: −11.16%
1 year: −14.36%

Valuation & ownership

Market cap: 1.90B
Enterprise value: 35.91B
P/E (ttm): 2.76
Forward P/E: -24.56
PEG ratio: —
Price / book: 10.47
Price / sales (ttm): 1.92
EV / EBITDA: 63.12
EPS (ttm): 10.52
EPS (forward): -1.18
Beta (5y monthly): 0.06
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 65.48M
Float: 474.38M
Short % of float: 8.28%
Short ratio (days): 10.63
Held by insiders: 25.45%
Held by institutions: 23.63%
Avg volume (3m): 277.16K
50-day average: 28.53
200-day average: 30.07
52-week change: −14.36%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 49.0
vs 50-day SMA: +1.66%
vs 200-day SMA: −3.33%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.87%
Realised vol (20d, ann.): 33.7%
From 52-week high: −19.84%
From 52-week low: +13.12%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

30.17

+3.84% implied

Low 21.27Median 25.20High 44.03

Recommendation trend

Now2 / 3 / 1
1m ago / 4 /

DES

About Lakefront Biotherapeutics

Yahoo Finance profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Sector: Healthcare
Industry: Biotechnology
Employees: 196
Headquarters: Mechelen, Belgium
Website: lakefrontbio.com
Officers: Mr. Henry O. Gosebruch CEO & Executive Director
Mr. Aaron L. Cox Chief Financial Officer
Ms. Christina Carlson J.D. Chief Operating Officer
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. Head of Investor Relations

SEAS

Seasonality · LKFT

2012–2026 · monthly returns

Strongest month Jul +7.21%Weakest month Aug −4.67%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3.6	-0.6	-10.9	-7.2	1.9	5.7	-9.2	4.7	4.0	-2.0			−11.2%
2025	-16.4	13.4	-3.7	7.2	6.8	-2.7	17.3	-4.2	10.2	-8.3	-1.4	4.4	+18.9%
2024	-7.6	-6.5	-8.3	-11.6	-2.2	-10.9	7.6	9.2	-1.1	-8.2	4.5	-0.5	−32.3%
2023	-0.5	-15.1	3.1	0.9	6.1	-1.7	4.2	-10.5	-8.8	-3.2	11.9	8.6	−8.4%
2022	22.4	-1.9	-6.4	-6.2	-5.4	1.4	-8.8	-1.7	-14.8	6.8	-12.7	11.6	−19.5%
2021	5.4	-20.8	-6.7	0.9	-2.1	-9.5	-12.1	-2.8	-10.6	0.7	-8.3	13.5	−44.3%
2020	7.8	-5.2	-7.3	12.5	-8.0	-2.7	-6.7	-27.7	6.6	-17.9	5.3	-19.3	−52.1%
2019	11.9	-4.9	20.7	-2.4	-1.2	13.5	34.5	-3.0	-9.2	20.5	6.4	5.6	+125.5%
2018	26.1	-11.9	-4.3	-10.7	14.2	-9.5	18.8	-7.5	10.9	-8.6	-2.0	-8.9	−2.2%
2017	1.4	8.4	22.2	0.8	-5.2	-7.1	3.7	16.6	10.0	-4.2	-9.5	6.3	+46.1%
2016	-22.2	-16.1	1.9	8.3	28.2	-4.5	-0.5	-1.6	19.1	-6.2	-2.5	8.6	+2.1%
2015	10.9	9.1	6.4	78.1	34.1	-9.5	17.8	-0.1	-32.8	17.9	3.6	26.5	+239.7%
2014	15.5	-6.3	-3.4	-2.0	3.5	-13.4	0.8	-15.5	-9.1	-6.5	15.8	14.3	−12.0%
2013	14.3	4.4	-4.1	8.2	-17.2	-7.8	9.3	-8.3	5.6	-8.6	4.1	4.7	−0.3%
2012			-11.4	-2.6	-2.6	6.3	15.2	-8.3	26.0	1.0	1.8	-1.2	+20.6%

13F

Investors Holding LKFT

latest 13F filings of 29 followed managers

Investors holding LKFT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$12.2M	0.02%	407.80K	+29%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

LKFT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LKFT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lakefront Biotherapeutics

Seasonality · LKFT

Insider Activity · LKFT

Congress Trades · LKFT

Investors Holding LKFT

Investors Holding LKFT

Congress Trades · LKFT

Insider Activity · LKFT

Seasonality · LKFT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lakefront Biotherapeutics

Financial Snapshot

Earnings & Dividends

News